$11.86
Omada Health, Inc.
Omda's updated fair value price target of NOK 57.0, trimmed from NOK 59, signals a subtle reset in expectations around what the shares might be worth under current modeling. Street research links this kind of move to a more balanced view of risk and reward, with firms weighing ongoing execution in Q4 and growth efforts against concerns around valuation and sector pressures. As you read on, you will see how to interpret these shifts and keep track of how the analyst story around Omda continues...
The average of price targets set by Wall Street analysts indicates a potential upside of 59.5% in Omada Health, Inc. (OMDA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
This stock continues to benefit from GLP-1 tailwinds -- and now it trades at a reasonable valuation.
In early March 2026, Omada Health, Inc. reported strong 2025 results with revenue of US$260.21 million, its first GAAP-profitable quarter, and issued 2026 revenue guidance of US$312 million to US$322 million alongside a US$49.57 million shelf registration for 3,644,941 common shares linked to an ESOP offering. The company also introduced GLP-1 Flex Care, a program that lets employees pay cash for obesity medications while receiving coordinated virtual care, giving employers a structured way...
Moby summary of Omada Health's Q4 2025 earnings call